Sarah Howell, Arecor's CEO, talks about its recent webinar on the need for fast-acting insulin treatments to deal with the obesity and diabetes epidemic sweeping the western world.
By 2030 it is estimated half of Americans will be obese, says Howell, and how to manage the disease and the cost of treatment will be a major problem.
Arecor’s ultra-fast acting insulin products are directly focused on dealing with this issue, Howell adds.